Skip to main content

Month: April 2026

Sysco Reports Third Quarter Fiscal Year 2026 Results

HOUSTON, April 28, 2026 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE:SYY) (“Sysco” or the “company”) today announced financial results for its 13-week third fiscal quarter ended March 28, 2026. Key financial results for the third quarter of fiscal year 2026 include the following (comparisons are to the same period in fiscal year 2025):Sales increased 4.7%; U.S. Foodservice volume increased 2.3%, U.S. local volumes increased 3.3%; Gross profit increased 6.5% to $3.8 billion; Operating income decreased 9.1% to $619 million, and adjusted operating income decreased 0.6% to $768 million1; Net earnings decreased 15.2% to $340 million, and adjusted net earnings decreased 3.6% to $452 million1; Cash flow from operations increased 11% to $1.5 billion and free cash flow2 increased 19% to $1.1 billion on a year-to-date basis; EBITDA decreased...

Continue reading

BBSI Introduces New HRIS Module: Performance Management

VANCOUVER, Wash., April 28, 2026 (GLOBE NEWSWIRE) — Barrett Business Services, Inc. (BBSI) (NASDAQ: BBSI), a leading provider of business management solutions and one of the largest professional employer organizations (PEO) in the U.S., today announced the upcoming launch of its newest HRIS module within the myBBSI Client Portal: Performance Management. This intuitive solution is designed to help organizations align with employees on objectives and expectations, and track and assess employee performance with consistency and clarity. The Performance Management module empowers employers to formalize performance expectations and document performance conversations through standardized review cycles, ongoing feedback, and development planning. By bringing these processes into a single, integrated platform, BBSI is helping clients strengthen...

Continue reading

Following Stockholder Approval, BIO-key Announces 1-for-10 Reverse Stock Split

HOLMDEL, N.J., April 28, 2026 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, today announced that it has approved a 1-for-10 reverse stock split that will become effective with the commencement of trading on April 30, 2026. BIO-key stockholders approved a proposal last week to allow the Board to proceed with a reverse split to assist the Company in its effort to regain compliance with the minimum bid price requirement. BIO-key had approximately 10.9 million shares of common stock issued and outstanding as of April 28, 2026. After giving effect to the 1-for-10 reverse stock split, BIO-key will have approximately 1.1 million shares of common stock issued and outstanding. BIO-key CEO Michael DePasquale commented, “The...

Continue reading

Nexera: KeepZone AI Receives Official Authorization to Introduce Advanced Fuel Tank Structural Survivability System in the Gulf Region

Tel Aviv, Israel, April 28, 2026 (GLOBE NEWSWIRE) — Nexera Technologies Ltd (“Nexera” or the “Company”) (Nasdaq: NEXR, NEXRW) (formerly known as Jeffs’ Brands Ltd), a data-driven company operating on the Amazon Marketplace expanding into the global homeland security sector through advanced artificial intelligence (“AI”) – driven solutions, today announced that its wholly-owned subsidiary, KeepZone AI Inc. (“KeepZone”), has received an official letter of authorization (the “Authorization”) from a provider of protective infrastructure solutions (the “Provider”) to introduce and represent the Provider’s advanced composite structural survivability system (the “System”) for fuel storage tanks and critical energy infrastructure with select clients in the Gulf region. The Authorization permits KeepZone to present the Provider’s technology,...

Continue reading

Aveanna to Participate at the Barclays 30th Annual Leveraged Finance Conference

ATLANTA, April 28, 2026 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Barclays 30th Annual Leveraged Finance Conference in Austin, TX on May 19, 2026. Management will host 1×1 investor meetings that day. About Aveanna Healthcare Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 38 states providing a broad range of pediatric and adult healthcare services including nursing, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, home health and hospice services, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families...

Continue reading

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in metastatic CNS cancers HOUSTON, April 28, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today a new payer coverage agreement with Blue Shield of California, effective April 2026, providing reimbursement for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay for patients with metastatic central nervous system cancers. Blue Shield of California joins a growing list of national and regional payers, including United Healthcare, Humana, and Highmark, that provide coverage for CNSide. The addition of Blue Shield of California expands CNSide’s total covered lives from approximately 75 million to 81 million, representing continued...

Continue reading

Watsco First Quarter Performance Reflects Stabilizing Markets, Improved Operating Efficiency and Expanded Technology Adoption

Company to Acquire Jackson Supply Company, Leading Sunbelt Distributor with Annual Sales of $230 Million MIAMI, April 28, 2026 (GLOBE NEWSWIRE) — Watsco, Inc. (NYSE: WSO) today announced its operating results for the first quarter ended March 31, 2026. Watsco also announced that it has entered into an agreement to acquire Jackson Supply Company, one of the largest Sunbelt HVAC distributors, with annual sales of $230 million. The transaction is expected to close in the second quarter of 2026, pending completion of customary closing conditions. Following closing, Jackson Supply will continue to be led by its existing management team, in keeping with Watsco’s long-standing approach of investing in great leaders and successful cultures. Watsco is the largest distributor in the highly fragmented North American HVAC market. Since...

Continue reading

Watsco To Acquire Jackson Supply Company

$230 Million Distributor Adds 25 Locations in Core Sunbelt Markets Buy-and-Build Opportunity Adds Scale and Leverages Long-Term Technology Advantage MIAMI, April 28, 2026 (GLOBE NEWSWIRE) — Watsco, Inc. (NYSE: WSO) announced today the signing of a definitive agreement to acquire Jackson Supply Company. Founded in 1972, Jackson Supply Company is one of the Sunbelt’s largest HVAC distributors with sales of $230 million in 2025. The Company serves approximately 5,000 customers from 25 locations in high-growth Sunbelt markets such as Texas, Louisiana, Tennessee, Alabama, Mississippi, Oklahoma and Arizona. Its diversified, balanced product offering includes Goodman and Amana brand HVAC equipment manufactured by Daikin Comfort Technologies North America, Inc. along with a broad array of supplies, accessories, and parts sourced from approximately...

Continue reading

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $930 – $945 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end –– Q1 2026 cash balance increased to $468.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 28, 2026 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported first quarter 2026 financial results and recent portfolio execution. “Five years from launch, Kiniksa continues to deliver strong...

Continue reading

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the trial remains on track to initiate in 2Q 2026 Combination and maintenance trials of WVE-007 on track to initiate in 2026 Data from RestorAATion-2 trial of WVE-006 (GalNAc-RNA editing) in AATD (including 400 mg monthly dose and 600 mg single dose cohorts) to be presented at an investor webcast during the ATS International Conference in May 2026 Regulatory feedback on accelerated approval pathway for WVE-006 continues to be expected mid-2026 CTA submission for WVE-008 (GalNAc-RNA editing for PNPLA3 I148M liver disease) on track for 2026 Well capitalized with cash and cash equivalents of $544.6 million as of March 31, 2026 and expected cash runway...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.